From 2020 to 2022, the number of prescriptions for these drugs quadrupled up to roughly 9 million in the final months of 2022, according to one analysis
Tirzepatide may also cause hypersensitivity reactions, which tend to affect 2-4% of the subjects in most studies [13]
Alongside breaking down existing fat, AOD9604 also suppresses fatty acid synthesis, limiting new fat formation
Currently, retatrutide has not been approved by the FDA as it is still in clinical phase 3 trials
Vooral de GLP-1-agonisten zorgden voor deze toename (+ 67 miljoen)
From a process development standpoint, peptide manufacturing is sensitive to synthesis conditions, purification efficiency, and storage